{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T18:48:26Z","timestamp":1773254906363,"version":"3.50.1"},"reference-count":38,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T00:00:00Z","timestamp":1743120000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T00:00:00Z","timestamp":1743120000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Hemodialysis International"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The advent of biological agents has provided significant therapeutic opportunities for patients with AA amyloidosis. However, when these patients reach end\u2010stage renal disease and begin dialysis, some clinicians may discontinue biological treatments due to the heightened risk of infections. Given that AA amyloidosis is a progressive condition, there is a potential for the disease to affect additional organs in these patients. Consequently, we aimed to evaluate the benefits and risks associated with biological agents in AA amyloidosis patients receiving dialysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>We performed a systematic literature review in Cochrane Database and MEDLINE about the use of biologic agents in AA amyloidosis patients undergoing dialysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We identified fifty\u2010five patients across twenty\u2010two studies. Familial Mediterranean fever was the etiology in 21 patients (71.4% anakinra and 28.6% canakinumab), rheumatoid arthritis in 17 patients (52.9% etanercept and 47.1% tocilizumab), unknown etiology in 8 patients (62.5% anakinra and 37.5% tocilizumab), ankylosing spondylitis in 5 patients (40% etanercept, 40% adalimumab, and 20% infliximab), hidradenitis suppurativa in 3 patients and tumor necrosis factor receptor\u2010associated periodic syndrome (TRAPS) in 1 patient. Biologic agents were effective or partially effective for primary disease control in 52 patients (94.5%). Two patients were able to discontinue dialysis. Most frequent side effects were infections (8 episodes in 7 patients). Eight patients died (5 due to infections, one due to cardiac causes and two due to pulmonary hemorrhage).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Biologic agents are effective in AA amyloidosis patients that are treated with dialysis and seem to have an acceptable safety profile.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/hdi.13238","type":"journal-article","created":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T16:27:31Z","timestamp":1743352051000},"page":"450-462","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Use of Biologic Therapy in\n                    <scp>AA<\/scp>\n                    Amyloidosis Patients Undergoing Dialysis\u2014A Systematic Literature Review"],"prefix":"10.1111","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4842-0683","authenticated-orcid":false,"given":"Ege Sinan","family":"Torun","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Division of Rheumatology University of Health Sciences, Prof. Dr. Cemil Ta\u015f\u00e7\u0131o\u011flu City Hospital  Istanbul Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G\u00fclay","family":"Kad\u0131o\u011flu","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Nephrology University of Health Sciences, Prof. Dr. Cemil Ta\u015f\u00e7\u0131o\u011flu City Hospital  Istanbul Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,3,28]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xkme.2022.100504"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1159\/000539596"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-024-01147-8"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keac223"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.55.6941"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.02470607"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10157-021-02160-2"},{"key":"e_1_2_7_9_1","first-page":"28","article-title":"Blockade of Interleukin\u20106 as a Possible Therapeutic Target for AA Amyloidosis","volume":"14","author":"Almenara Tejederas M.","year":"2021","journal-title":"Nefrologia (English Edition)"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/hdi.12993"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-014-2772-2"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.3109\/13506129.2014.1002031"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/6819476"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-012-2646-3"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000007859"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-020-05283-1"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.3109\/13506129.2011.636460"},{"issue":"1","key":"e_1_2_7_18_1","first-page":"33","article-title":"Hidradenitis Suppurativa: A Lesser\u2010Known Cause of AA Amyloidosis","volume":"24","author":"Helvac\u0131 \u00d6.","year":"2020","journal-title":"Hippokratia"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-010-1457-7"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.090101"},{"issue":"6","key":"e_1_2_7_21_1","first-page":"S46","article-title":"Therapeutic Blockade of Interleukin\u20106 by Tocilizumab in the Management of AA Amyloidosis and Chronic Inflammatory Disorders: A Case Series and Review of the Literature","volume":"33","author":"Lane T.","year":"2015","journal-title":"Clinical and Experimental Rheumatology"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1080\/13506129.2017.1352503"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/823093"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfn646"},{"issue":"4","key":"e_1_2_7_25_1","first-page":"518","article-title":"Efficacy of Etanercept in Patients With AA Amyloidosis Secondary to Rheumatoid Arthritis","volume":"25","author":"Nakamura T.","year":"2007","journal-title":"Clinical and Experimental Rheumatology"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-011-1782-6"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfr528"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1080\/14397595.2018.1457469"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-018-3993-5"},{"issue":"3","key":"e_1_2_7_30_1","first-page":"343","article-title":"Clinical Outcome and Survival of Secondary (AA) Amyloidosis","volume":"21","author":"Tanaka F.","year":"2003","journal-title":"Clinical and Experimental Rheumatology"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa070265"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kead465"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1080\/0886022X.2024.2321320"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.11163"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2009.11.010"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa211"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.3109\/14397595.2013.854048"},{"issue":"7","key":"e_1_2_7_38_1","first-page":"644","article-title":"Outcome of 121 Patients With Renal Amyloid a Amyloidosis","volume":"19","author":"Ahbap E.","year":"2014","journal-title":"Journal of Research in Medical Sciences"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1086\/424516"}],"container-title":["Hemodialysis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hdi.13238","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/hdi.13238","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hdi.13238","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T01:30:58Z","timestamp":1773192658000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/hdi.13238"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,28]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.1111\/hdi.13238"],"URL":"https:\/\/doi.org\/10.1111\/hdi.13238","archive":["Portico"],"relation":{},"ISSN":["1492-7535","1542-4758"],"issn-type":[{"value":"1492-7535","type":"print"},{"value":"1542-4758","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,28]]},"assertion":[{"value":"2024-12-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-14","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}